VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Source: ClinicalTrials.gov NCT05780281 ↗Summary
Linked Publications
-
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Sustained Recovery |
160; 151 | — |
| PRIMARY Number of Participants With an Ordinal Outcome on Day 5 |
0; 1; 2; 3; 10; 14 | — |
| SECONDARY Number of Participants Who Died From All Causes |
14; 13 | — |
| SECONDARY Number of Participants With a Safety Outcome Through Day 5 |
36; 44 | — |
| SECONDARY Number of Participants With a Safety Outcome Through Day 28 |
51; 58 | — |
| SECONDARY Number of Participants With a Safety Outcome Through Day 90 |
42; 48 | — |
Eligibility Criteria
Inclusion Criteria: Refer to the master protocol (NCT04501978)
Exclusion Criteria: Refer to the master protocol (NCT04501978)
Additional Exclusion Criteria:
- Pregnant women
- Nursing mothers
In addition, prior to the initial futility assessment which is performed when approximately 150 participants have been enrolled on VIR-7831 and 150 on placebo, patients on highflow oxygen or non-invasive ventilation (category 5 of the pulmonary ordinal outcome) will be excluded. These patients may be eligible for the trial if the initial futility assessment is passed by this agent.
Data sourced from ClinicalTrials.gov (NCT05780281) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.